LONDON – A 2.5-year investigation into the low level of uptake of biosimilars in Europe has concluded that – in the absence of automatic substitution – a hearts-and-minds education campaign covering physicians, payers and patients is the only lever that can be pulled at a pan-European level to drive the growth of the market.